DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Government-administered direct-to-consumer rail launched January 2026. Sliding-scale pricing through 2028. Medicare Part D members eligible for $50 copay on FDA-approved indications.
TrumpRx is new and evolving.
Launched January 2026 under the Most Favored Nation drug pricing executive order. Manufacturer participation, drug coverage, and pricing schedules are subject to change quarterly. Verify specific pricing at TrumpRx.gov before relying on these numbers for purchasing decisions.
3 questions to determine if you qualify for the $50/month copay tier (launched January 2026).
1. What\'s your age?
| Product | Current price | Medicare $50 tier |
|---|---|---|
| Foundayo (oral tirzepatide) Tirzepatide (oral, orforglipron prodrug) | $300/mo | $50/mo |
| Wegovy Pill (oral semaglutide 25mg) Semaglutide (oral, 25mg) | $300/mo | $50/mo |
| Mounjaro Tirzepatide | $325/mo | $50/mo |
| Ozempic Semaglutide | $320/mo | $50/mo |
| Zepbound Tirzepatide | $350/mo | $50/mo |
| Wegovy Semaglutide | $350/mo | $50/mo |
Current price = January 2026 launch price. Medicare $50 tier requires Part D enrollment + FDA-approved indication. Projected 2028 = sliding-scale endpoint per TrumpRx negotiation terms.
~$350/mo today → $245/mo by 2028. Medicare $50 copay tier available. Single application; ships to all US states.
$499-$549/mo cash-pay direct from manufacturer. No insurance, no PBM. Limited to specific products (e.g., Foundayo $549).
Transparent markup over wholesale. GLP-1 access expanding 2026. Generally cheaper than retail but pricier than TrumpRx Medicare tier.
$199-$299/mo for compounded semaglutide/tirzepatide. Lowest cash price but unverified purity + FDA enforcement risk.
TrumpRx is a government-administered direct-to-consumer drug platform launched January 2026 under the Trump administration's Most Favored Nation pricing executive order. It negotiates directly with manufacturers, bypassing PBMs to reduce consumer prices.
Medicare Part D enrollees can access GLP-1s at $50/month copay for FDA-approved indications: Type 2 diabetes (Ozempic, Mounjaro, Foundayo), and OSA + obesity (Zepbound). Weight-loss-only indications remain statutorily excluded by Part D.
TrumpRx negotiated 24-month price reductions with manufacturers. January 2026 launch prices ($350/mo for GLP-1) drop to projected $245/mo by January 2028 as manufacturer rebates compound. Already-purchased prescriptions retain their original price.
Yes — TrumpRx cash-pay is available to any US resident with a valid prescription. Cash prices are higher than the Medicare copay tier ($245-$350 vs $50) but still cheaper than retail pharmacy ($1,349/mo).
No. Cost Plus Drugs (Mark Cuban) is a private cash-pay pharmacy with transparent markup over wholesale. TrumpRx is a government platform with negotiated manufacturer pricing and a Medicare copay tier. They're complementary — compare both for your specific situation.